Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1972 1
1975 1
1980 2
1982 3
1983 46
1984 120
1985 124
1986 121
1987 141
1988 190
1989 160
1990 171
1991 189
1992 185
1993 216
1994 191
1995 220
1996 250
1997 353
1998 384
1999 496
2000 537
2001 540
2002 731
2003 747
2004 877
2005 999
2006 1132
2007 1441
2008 1479
2009 1636
2010 1819
2011 1912
2012 2163
2013 2358
2014 2509
2015 2438
2016 2577
2017 2626
2018 2517
2019 1172
2020 26
Text availability
Article attribute
Article type
Publication date

Search Results

32,433 results
Results by year
Filters applied: . Clear all
Page 1
[Treatment of type 2 diabetes mellitus in elderly patients].
Gómez-Huelgas R, et al. Rev Esp Geriatr Gerontol 2018. Among authors: Mediavilla Bravo JJ, Miranda C. PMID 29439834 Spanish.
The prevalence of type 2 diabetes mellitus (DM2) increases markedly with age. Antidiabetic treatment and the objectives of glycaemic control in elderly patients with DM2 should be individualised according to their biopsychosocial characteristics. ...
The prevalence of type 2 diabetes mellitus (DM2) increases markedly with age. Antidiabetic treatment and the objectives …
Metformin in cancer treatment and prevention.
Morales DR and Morris AD. Annu Rev Med 2015 - Review. PMID 25386929
Patients with diabetes mellitus are at increased risk of cancer development. Metformin is a well-established, effective agent for the management of type 2 diabetes mellitus. ...Basic science has provided a better understanding of the mechanism of action of metformin and the potential for metformin to modulate molecular pathways involved in cancer cell signaling and metabolism. ...
Patients with diabetes mellitus are at increased risk of cancer development. Metformin is a well-established, effective …
Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis.
Mishriky BM, et al. Diabetes Metab 2018 - Review. PMID 29477373
METHODS: We searched for randomized trials comparing SGLT-2i to DPP-4i as add-on therapy to metformin in Type 2 diabetes.We pooled trials reporting outcomes between 12 and 26 weeks together while trials reporting results ≥52 weeks were pooled together. ...CONCLUSION: While both SGLT-2i and DPP-4i can reduce A1c, SGLT-2i causes a more robust A1c reduction and more weight loss but with more genital infections. ...
METHODS: We searched for randomized trials comparing SGLT-2i to DPP-4i as add-on therapy to metformin in Type 2 diabetes
Monotherapy in patients with type 2 diabetes mellitus.
Rhee SY, et al. Korean J Intern Med 2017 - Review. Among authors: Moon MK. PMID 29057643 Free PMC article.
In order to improve the quality of life and to prevent chronic complications related to diabetes mellitus, intensive lifestyle modification and proper medication are needed from the early stage of diagnosis of type 2 diabetes mellitus (T2DM). ...If metformin is difficult to use as a first-line treatment, other appropriate medications should be selected in view of the clinical situation. ...
In order to improve the quality of life and to prevent chronic complications related to diabetes mellitus, intensive lifestyle …
Pharmacogenetics: Implications for Modern Type 2 Diabetes Therapy.
Staiger H, et al. Rev Diabet Stud 2015 - Review. PMID 27111121 Free PMC article.
In recent years, it has also entered the field of clinical diabetes research. In modern type 2 diabetes therapy, metformin is established as first-line drug. ...Moreover, some new and promising candidate genes for future pharmacogenetic assessment are highlighted. Finally, we critically appraise the current state of type 2 diabetes pharmacogenetics in the light of its impact on therapeutic decisions, and we refer to major problems, and make suggestions for future efforts in this field to help improve the clinical relevance of the results, and to establish genetically determined treatment failure....
In recent years, it has also entered the field of clinical diabetes research. In modern type 2 diabetes therapy, met
[Management of type 2 diabetes mellitus therapy in a mature age].
Hradec J and Račická E. Vnitr Lek 2016. PMID 27180673 Czech.
Type 2 diabetes mellitus represents a serious medical, social and economic problem, since it has become a pandemic in recent years, affecting up to 1/3 of the Czech population in old age. ...The target values of diabetes compensation are derived from them. The purpose of the paper is to describe the possibilities of safe therapy for type 2 diabetes mellitus in older patients and draw attention to the risks that some types of treatment may present for older people....
Type 2 diabetes mellitus represents a serious medical, social and economic problem, since it has become a pandemic in r …
Repurposing metformin for the prevention of cancer and cancer recurrence.
Heckman-Stoddard BM, et al. Diabetologia 2017 - Review. PMID 28776080 Free PMC article.
Multiple epidemiological studies have documented an association between metformin, used for treatment of type 2 diabetes, and reduced cancer incidence and mortality. Cell line models may not accurately reflect the effects of metformin in the clinical setting. Moreover, findings from animal model studies have been inconsistent, whilst those from more recent epidemiological studies have tempered the overall effect size. ...
Multiple epidemiological studies have documented an association between metformin, used for treatment of type 2 diabetes
Metformin: historical overview.
Bailey CJ. Diabetologia 2017. PMID 28776081
Metformin (dimethylbiguanide) has become the preferred first-line oral blood glucose-lowering agent to manage type 2 diabetes. ...Long-term cardiovascular benefits of metformin were identified by the UK Prospective Diabetes Study (UKPDS) in 1998, providing a new rationale to adopt metformin as initial therapy to manage hyperglycaemia in type 2 diabetes. ...
Metformin (dimethylbiguanide) has become the preferred first-line oral blood glucose-lowering agent to manage type 2 diabet
A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus.
Chawla G and Chaudhary KK. Diabetes Metab Syndr 2019 - Review. PMID 31235127
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are the latest class of drugs to be introduced for the treatment of type 2 diabetes mellitus (T2DM). ...Mostly reported adverse events are genital mycotic infections, while urinary tract infections and events linked to volume depletion are rather rare. ...
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are the latest class of drugs to be introduced for the treatment of type 2 diabetes
32,433 results
Jump to page
Feedback